{"id":"W2898602366","doi":"10.1093/annonc/mdy285.157","title":"Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant ovarian cancer (PROC): Initial results of an expansion cohort from FORWARD II, a phase Ib study","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Pembrolizumab; Tolerability; Internal medicine; Ovarian cancer; Oncology; Response Evaluation Criteria in Solid Tumors; Adverse effect; Cohort; Interquartile range; Cancer; Phases of clinical research; Immunotherapy; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002139572,0.0008478488,0.001015063,0.0003385409,0.0003286253,0.0007566196,0.0005158465,0.0006307371,0.001172523],"category_scores_gemma":[0.0009333859,0.0004058689,0.0008046903,0.0003568084,0.0004773531,0.0006539165,0.0002866181,0.001616741,0.0004302841],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008823486,"about_ca_system_score_gemma":0.0009122742,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001120442,"about_ca_topic_score_gemma":0.002967599,"domain_scores_codex":[0.9994903,0.0002214629,0.00003427978,0.00008608685,0.00008841076,0.00007948865],"domain_scores_gemma":[0.9994281,0.000101149,0.00008384855,0.00006424466,0.00006079744,0.0002618729],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3220021,0.06858065,0.05957111,0.001113172,0.00270412,0.0009262058,0.001201124,0.0062277,0.17984,0.0002597448,0.006360744,0.3512134],"study_design_scores_gemma":[0.1379444,0.7014158,0.1151381,0.0001040905,0.001824269,0.002286124,0.0002109156,0.002803731,0.02875354,0.0001999527,0.009264291,0.00005481929],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957995,0.002148483,0.0002528431,0.0001396966,0.00002304914,0.0003796638,0.000323543,0.00003249839,0.0009007531],"genre_scores_gemma":[0.9943452,0.001633249,0.0009278056,0.0002438436,0.00004784425,0.0003003123,0.001571179,0.00002300514,0.0009076294],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002139572,"threshold_uncertainty_score":0.01131523,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04508941207630825,"score_gpt":0.410968884633746,"score_spread":0.3658794725574378,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}